PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy

This study evaluated the sintilimab combination of bevacizumab and tafolecimab in NSCLC patients who have previously been treated with anti- PD- 1/ligand (L)1 and acquired resistance. The patients were assigned to receive sintilimab(200mg Q3W) in combination with bevacizumab(7.5mg/kg Q3W) and tafolecimab(600 mg Q6W). The primary endpoints of the study were progression- free survival (PFS) assessed by RECISTv1.1 , while secondary endpoints included objective response rate (ORR), and overall survival (OS) and safety.

NCT Number	NCT07014215
Lead Sponsor	Anhui Provincial Cancer Hospital
Conditions	NSCLC (Advanced Non-small Cell Lung Cancer), Resistance to Immunotherapy
Enrollment	52 participants
Start Date	2025-06
Primary Completion	2027-05 (estimated)
Study Completion	2029-05 (estimated)
Updated on ClinicalTrials.gov	2025-06-10